Eledon Pharmaceuticals In... (ELDN)
| Bid | 2.92 |
| Market Cap | 179.05M |
| Revenue (ttm) | 192K |
| Net Income (ttm) | -35.32M |
| EPS (ttm) | -0.75 |
| PE Ratio (ttm) | -3.99 |
| Forward PE | -2.81 |
| Analyst | Buy |
| Ask | 3.5 |
| Volume | 143,748 |
| Avg. Volume (20D) | 235,388 |
| Open | 3.02 |
| Previous Close | 3.00 |
| Day's Range | 2.96 - 3.07 |
| 52-Week Range | 1.77 - 5.54 |
| Beta | 0.67 |
About ELDN
Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that is a molecule expressed on the surface of human immune system T cells, which is in Phase 2a clinical tri...
Analyst Forecast
According to 1 analyst ratings, the average rating for ELDN stock is "Buy." The 12-month stock price forecast is $16, which is an increase of 435.12% from the latest price.
Stock Forecasts
2 months ago · seekingalpha.com
Eledon Pharmaceuticals: At The Forefront Of The Organ Transplant Management BusinessEledon Pharmaceuticals' Tegoprubart, a second-gen anti-CD40L antibody, shows promise in preventing organ rejection without thromboembolic risks, addressing unmet needs in kidney and islet cell transpl...